Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

The potential of innovative trial design for efficiently evaluating repurposed drugs

Innovative approaches to conducting proof-of-concept trials could accelerate the evaluation of repurposed drugs. Drawing lessons from repurposing efforts for COVID-19 therapies, here we present a vision for a drug repurposing platform that could maximize efficiency and improve patient outcomes for many different conditions.
  1. James M. S. Wason

    1. Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Oliver Bandmann

    1. Sheffield Institute for Translational Neuroscience (SITraN), Department of Neuroscience, The University of Sheffield, Sheffield, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Introduction

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 22, 681-682 (2023)

doi: https://doi.org/10.1038/d41573-023-00129-2

Acknowledgements

J.M.S.W. is funded by a NIHR Research Professorship (NIHR301614).

References

  1. Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41–58 (2019).

    Article  PubMed  Google Scholar 

  2. Tang, Y., Yang, K., Zhao, J., Liang, X. & Wang, J. Evidence of repurposing drugs and identifying contraindications from real world study in Parkinson’s disease. ACS Chem. Neurosci. 10, 954–963 (2019).

    Article  PubMed  Google Scholar 

  3. Woodcock, J. & LaVange, L. M. Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med. 377, 62–70 (2017).

    Article  PubMed  Google Scholar 

  4. Zheng, H., Jaki, T. & Wason, J. M. S. Bayesian sample size determination using commensurate priors to leverage preexperimental data. Biometrics 79, 669–683 (2023).

    Article  PubMed  Google Scholar 

  5. Austin, C. P., Mount, B. A. & Colvis, C. M. Envisioning an actionable research agenda to facilitate repurposing of off-patent drugs. Nat. Rev. Drug Discov. 20, 723–724 (2021).

    Article  PubMed  Google Scholar 

Download references

Supplementary Information

  1. Supplementary information

Competing Interests

The authors declare no competing interests.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links